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Background: Design and execution of immunotherapy trials for seasonal allergies may be complicated by
numerous factors including variable allergy testing methods, pollen levels, and timing and intensity of other
seasonal allergens. We evaluated grass allergy immunotherapy tablet (AIT) treatment in North American adults with
grass pollen-induced allergic rhinitis with or without conjunctivitis (AR/C), with/without asthma.
Methods: Subjects age 18–65 with clinical history of grass pollen–induced AR/C, with/without asthma were
randomized 1:1 to once-daily 2800 BAU Timothy grass AIT (oral lyophilisate, Phleum pratense, 75,000 SQ-T,
containing approximately 15 μg of Phl p 5) or placebo. The AR/C symptom and medication scores were recorded
daily. The primary end point was the average AR/C daily symptom score (DSS) during the entire grass pollen season
(GPS). Ranked key secondary end points were Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score, daily
medication score (DMS), and percentage of well days, all over entire GPS. Safety was monitored through adverse
event reporting.
Results: Efficacy analysis included 289 subjects. Over the entire GPS, mean DSS was 6% lower with AIT versus
placebo (5.69 vs. 6.06), but this difference was not statistically significant (p = 0.3475) despite significantly higher
immunological response in the grass AIT group. No significant between-group differences were seen for key
secondary end points. In general, DSS was high before GPS began and no clear relationship between DSS and
grass pollen counts was seen during GPS. In post hoc analysis of subjects with pre-seasonal DSS ≤3, mean DSS and
DMS were both significantly lower with grass AIT versus placebo (27%; p = 0.0327 and 68%; p = 0.0060, respectively).
In this subgroup a relationship between DSS and grass pollen counts was observed. Grass AIT was generally well
tolerated, with no events of anaphylactic shock or respiratory compromise.
Conclusions: In this trial, 2800 BAU grass AIT did not demonstrate significant symptom improvement versus
placebo. Lack of relationship between pollen count and symptom score in the study population, and post hoc
findings among subjects with low pre-seasonal symptoms, suggest that the symptoms reported in this study were
not primarily reflective of the effects of grass pollen exposure.
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Table 1 Subject disposition
Placebo Grass AIT
N (%) N (%)
Full analysis set (FAS) 166 (100%) 163 (100%)
Per protocol (PP) 119 (72%) 121 (74%)
Subjects with diary data (entire GPS) 150 (90%) 139 (85%)
Subjects with diary data (peak GPS) 143 (86%) 137 (84%)
Withdrawn from trial 26 (16%) 27 (17%)
Reason for withdrawal
Withdrawal of consent 7 (4%) 8 (5%)
Lost to follow-up 5 (3%) 2 (1%)
Non-compliance with protocol 3 (2%) 1 (<1%)
Pregnancy 2 (1%) 0 (0%)
Adverse event 5 (3%) 10 (6%)
Other 4 (2%) 6 (4%)
Withdrawal initiated by
Investigator 6 (4%) 7 (4%)
Sponsor 1 (<1%) 0 (0%)
Subject 19 (11%) 20 (12%)
Completed 140 (84%) 136 (83%)
9 of the subjects with data in the grass pollen season dropped out before the
peak grass pollen season and thus did not provide any data in the peak grass
pollen season.
% = percentage of the full analysis set (all randomized subjects). AIT Allergy
immunotherapy tablet, GPS Grass pollen season.
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In Europe, Timothy grass allergy immunotherapy tablet
(AIT) treatment is an approved means of administering
immunotherapy sublingually to patients who are sensi-
tized to Timothy and related grass pollens, and it has been
approved by regulatory authorities for the disease-
modifying treatment of grass pollen-induced allergic rhin-
itis with or without conjunctivitis (AR/C) [1]. Unlike
symptomatic treatment, grass AIT has been shown to pro-
vide significant improvements in AR/C symptoms and
medication use 2 years after cessation of treatment [1].
Conventional subcutaneous immunotherapy also has
disease-modifying potential and has been used for more
than a century, but it requires repeated in-office injections
[2] and in some cases has been associated with severe ana-
phylaxis, including fatal reactions [3,4]. Sublingual allergy
immunotherapy delivered via rapidly dissolving tablets is a
relatively new, more convenient treatment modality that
appears to be associated with a positive safety profile [5].
Compared with trials for symptomatic AR/C treatments,
the design and execution of immunotherapy clinical trials
is complex. In pharmacotherapy studies, subjects with
AR/C are typically enrolled once their symptoms have
reached a predefined level of severity, and the ability of
the target agent to reduce symptoms can be observed
within hours to days of initiation [6]. In trials of immuno-
therapy for seasonal allergies, treatment is initiated weeks
or months prior to the onset of pollen season and the as-
sociated symptoms, to allow the treatment to modulate
the immune system before the season starts [7]. Therefore,
subjects are enrolled based on symptoms experienced in
previous seasons; however, the severity of symptoms in
previous seasons may not be an accurate predictor of up-
coming symptoms due to several complicating factors [6].
Variable pollen levels, potential exposure to other aller-
gens, pollutant exposure, weather patterns, allergen avoid-
ance measures, disease progression, and methods of
allergy testing can all exert effects on the results observed
in a trial of seasonal allergy immunotherapy. We evaluated
treatment with SCH 697243/MK-7243, a Timothy grass
AIT formulation of 2800 bioequivalent allergen units
(BAU), in North American adults with grass pollen-
induced AR/C with or without asthma.
Results and discussion
Demographics and baseline characteristics
Of the 405 subjects who were screened, 329 subjects
were randomized and were included in the safety analysis
(76 [19%] subjects were screening failures). The efficacy
analysis included 150 placebo-treated subjects and 139
grass AIT–treated subjects who completed at least 1 diary
entry during the grass pollen season (GPS). In total, 140
(84%) and 136 (83%) subjects in the placebo and grass
AIT groups completed the trial, whereas 26 (16%) and 27(17%) in each group, respectively, withdrew prematurely.
Among withdrawals, 15 (5%) were due to adverse events
(AEs). The pattern of withdrawal was similar between
treatment groups (Table 1).
Demographic and baseline characteristics were well bal-
anced between treatment arms (Table 2). The majority of
subjects were white (81%), mean age was 35.9 years, and
mean duration of grass pollen allergy was 21 years. Asthma
as a coexisting condition was well represented in both
groups (grass AIT, 28%; placebo, 26%). Prevalence of
sensitization to other allergens was high in both treatment
groups. Pre-season symptom scores (over the 14 days be-
fore start of GPS) were high in both groups; 67% of subjects
had a pre-season AR/C daily symptom score (DSS) >3.
Grass pollen season
The GPS had a mean duration of 43 days. Mean daily
pollen counts were 44 grains/m3 and 61 grains/m3 over
the entire and peak GPS, respectively. The pre-seasonal
treatment period was approximately 16 weeks (range: 6–
24 weeks).
Efficacy: primary and key secondary end points
In general, DSS was high both before and during the
GPS, and for the entire study population no clear rela-
tionship between DSS and grass pollen counts was ob-
served during the GPS (Figure 1A). Over the entire GPS,





Female, no. (%) 88 (53%) 88 (54%)
Race, no. (%)
White 134 (81%) 134 (82%)
Black 21 (13%) 21 (13%)
Hispanic/Latino 6 (4%) 4 (2%)
Non-smoker 121 (73%) 128 (79%)
Previous smoker, no. (%) 24 (14%) 26 (16%)
Smoker, no. (%) 21 (13%) 9 (6%)
Age, y
Mean (SD) 35.9 (11.7) 35.9 (11.7)
Range 18-62 18-65
Subjects with asthma, no. (%) 43 (26%) 46 (28%)
Sensitive to non-grass allergens
per skin prick, no. (%)
White oak 74 (45%) 75 (46%)
White birch 84 (51%) 87 (53%)
Animal hair/dander (cat) 77 (46%) 79 (48%)
House dust mite 86 (52%) 93 (57%)
Mean duration of pre-treatment
(weeks), [range]
16.2 [5.9, 23.9] 16.3 [6.4, 23.7]
AIT Allergy immunotherapy tablet, DSS Daily symptom score, SD
Standard deviation.
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pared with the placebo group (5.69 vs. 6.06), but this dif-
ference was not statistically significant (p = 0.3475)
(Table 3). Despite high symptom scores both before and
during the pollen season, symptomatic medication use
was low in both groups, with 42% of grass AIT subjects
and 43% of placebo subjects not using any rescue medi-
cation during the GPS. The mean daily medication score
(DMS) was numerically lower (27%; p = 0.0827) in the
grass AIT group (1.07) relative to placebo (1.47). No sig-
nificant differences between groups were seen for averagePollen counts Gra
A B
-20 -10 0 10 20 30 40 50 60






























-20 -10 0 10 20
Days from defined p
Subjects with average pre-
Figure 1 Average daily symptom scores in (A) all subjects, (B) subject
with average pre-seasonal symptom score >3. AIT = allergy immunotheRhinoconjunctivitis Quality of Life Questionnaire with
standardized activities (RQLQ[S]) score (grass AIT = 1.36,
placebo = 1.44; p = 0.5293) or for percentage of AR/C well
days (grass AIT = 27%, placebo = 26%; p = 0.6965).
Other efficacy end points
At the end of the GPS, the subjects answered the question,
“Compared to your rhinoconjunctivitis symptoms in the
previous grass pollen season, how have you felt overall in
this grass pollen season?” Scoring is summarized in
Figure 2. Data were pooled into the binary end point of
improved (including those who answered “much better”
or “better”) or not improved (those who answered “the
same,” “worse,” or “much worse”). Results demonstrate
that 69% of the subjects in the grass AIT group indicated
improvement, compared with 49% who received placebo
(odds ratio 2.24, p = 0.0010).
Additional efficacy variables (listed in Methods) failed to
show significant differences between grass AIT and
placebo.
Post hoc subgroup analysis of efficacy
A post hoc analysis divided subjects into those with low
pre-seasonal symptoms (DSS ≤3; 33% of all subjects)
and those with high pre-seasonal symptoms (DSS >3;
67% of all subjects). In those with pre-seasonal DSS ≤3,
mean DSS and mean DMS were both significantly lower
over the GPS in the grass AIT group compared with the
placebo group (27%; p = 0.0327 and 68%; p = 0.0060 re-
spectively). Furthermore, the symptom scores in this
subgroup closely corresponded to pollen exposure
(Figure 1B). In subjects with pre-season DSS >3, no sig-
nificant differences between grass AIT and placebo were
seen for mean DSS or DMS (p > 0.05), and no clear rela-
tionship between DSS and grass pollen counts was
observed (Figure 1C).
Although a clinical history of a potentially overlapping
seasonal or perennial allergic disease was an exclusion-20 -10 0 10 20 30 40 50 60
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Table 3 DSS, DMS, RQLQ(S) scores* and percent well days during the grass pollen season
Placebo (n = 166) Grass AIT (n = 163) Difference 95% CI for difference P value
DSS, mean (SE) 6.06 (.40) 5.69 (.39) −0.37 [−0.41; 1.16] 0.3475
DMS, mean (SE) 1.47 (.22) 1.07 (.20) −0.40 [−0.05; 0.85] 0.0827
RQLQ(S)† score, mean (SE) 1.44 (.12) 1.36 (.12) −0.08 [−0.16; 0.32] 0.5293
Percent well days, mean (SE) 26.03 (3.13) 27.44 (3.29) 1.42 [−8.56; 5.73] 0.6965
*Scores were adjusted using the analysis of variance (ANOVA) model, with treatment group as fixed effect and pollen region as random effect. †RQLQ(S): number
of observations: placebo = 840, Grass AIT = 801. AIT Allergy immunotherapy tablet, CI Confidence interval, DMS Daily medication score, DSS Daily symptom score,
RQLQ(S) Rhinoconjunctivitis quality of life questionnaire with standardized activities, SE Standard error.
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performed on subject subsets based on sensitization pro-
files to assess the effect of non-grass allergens on efficacy
outcomes. These subsets included subjects who were SPT-
negative to 1) oak, 2) birch, 3) house dust mite (HDM),
and 4) hair and dander. An additional subset included only
subjects who were monosensitized to grass pollen. Results
in these subsets were consistent with those seen in the en-
tire study population, in that no significant difference be-
tween grass AIT and placebo was observed in any of these
subsets for the outcomes of mean changes in DSS or DMS.Immunologic measures
Specific IgE and IgG4 levels were similar in both groups at
baseline (visit 1; screening). Between visit 1 and visit 4 (pre-
season), specific IgE levels increased in the grass AIT group,
indicating an immunologic response to treatment. In the
placebo group, specific IgE levels increased only after the
start of the GPS and remained significantly lower compared
with the grass AIT group. By the time of the pre-season
visit, change from baseline in log-transformed IgG4 levels
were significantly greater in the grass AIT group compared
with those in the placebo group (p < 0.0001) (Figure 3).
This treatment effect continued through the end of the sea-
son (p < 0.0001). A significantly higher induction of IgE-
blocking antibodies as compared to baseline was observed
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Safety
Grass AIT treatment was generally well tolerated. There
were no events of anaphylactic shock or respiratory com-
promise. No new safety signals were detected. Table 4
shows AEs reported after the beginning of treatment;
treatment-emergent AEs were experienced by 121/163
subjects (74%) in the grass AIT group and 101/166 subjects
(61%) in the placebo group. Discontinuations due to AEs
were infrequent with both grass AIT treatment (10/163;
6%) and placebo (5/166; 3%). Six of the 10 withdrawals in
the grass AIT group were considered to be possibly or
probably treatment-related.
Treatment-related AEs were experienced by 57% of sub-
jects in the grass AIT group and 15% of subjects in the pla-
cebo group. Table 5 lists the treatment-related AEs with an
incidence of 5% or greater. The most common treatment-
related AEs reported in the grass AIT group were ear prur-
itus, mouth edema, oral pruritus, oral paresthesia, and
throat irritation. The median number of consecutive days
in which local application-site reactions were reported to
occur at any time during the day in the grass AIT group
ranged from 1 to 16 days. Most treatment-related AEs
were mild to moderate in severity both in the grass AIT
group (percentage of subjects experiencing mild AEs: 61%;
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Figure 3 Specific IgG4 over time. AIT = allergy immunotherapy tablet.
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vere treatment-related AEs occurred in 6 subjects. Severe
treatment-related AEs reported in the grass AIT group in-
cluded 2 episodes each of urticaria and diarrhea, and 1 epi-
sode each of Eustachian tube obstruction, abdominal pain,
and lip blister. There was also 1 severe treatment-related
headache in the placebo group.
Two treatment-related asthma events were reported dur-
ing the treatment period in the grass AIT group versus 1 in
the placebo group; all were assessed as mild in severity. No
subjects in the grass AIT group discontinued due to asthma
events. Two serious adverse events were reported, both re-
lated to falls and both in the placebo group.
Three subjects, all in the grass AIT group, were adminis-
tered epinephrine. The first subject experienced a moder-
ate anaphylactic reaction, as assessed by the investigator,Table 4 Summary of treatment-emergent AEs
Placebo (n = 166) Grass AIT (n = 163)
N (%)* Events N (%)* Events
All 101 (61) 258 121 (74) 454
Causality
Probably related 11 (7) 23 73 (45) 184
Possibly related 13 (8) 29 20 (12) 29
Unlikely related 93 (56) 206 95 (58) 241
Severity
Mild 70 (42) 146 100 (61) 268
Moderate 57 (34) 94 75 (46) 156
Severe 14 (8) 18 20 (12) 30
*Represents all subjects experiencing AE of each causality/severity; each
subject could experience AEs in multiple categories of causality/severity. AE
Adverse event, AIT Allergy immunotherapy tablet.5 minutes after first dose. Symptoms included swelling of
lips; itchy mouth, tongue, and throat; and dysphagia. The
subject was treated on site with antihistamine and epi-
nephrine; the event resolved, and the subject was with-
drawn from the study. The second subject experienced
itchy throat, itchy mouth, dry cough, labial hive, post-
nasal drip, and uvula erythema immediately after first
dose. The subject was treated on site with antihistamine,
epinephrine, and oral prednisone. The event resolved, and
the subject was withdrawn from the study. The third sub-
ject experienced a systemic allergic reaction assessed as
mild by the investigator 6 minutes after first dose. Symp-
toms included itching under the tongue, throat, ears and
nose, sneezing, rhinorrhea, and throat irritation. The sub-
ject was treated on site with antihistamine and epineph-
rine, and the event resolved. This subject experienced
another systemic allergic reaction the next day which re-
solved without treatment, and the subject continued in
the trial. Two additional subjects in the grass AIT group
experienced systemic reactions (one subject: symptoms of
lightheadedness, headache, sleepiness, and itching of ears;
one subject: symptoms of lightheadedness and itching in
mouth) after the first treatment dose but did not receive
epinephrine. These subjects also recovered without seque-
lae and continued in the trial. There were no signs of
hypotension in any of these 5 subjects.
Discussion
In the current study, no significant differences between
grass AIT and placebo were observed for the primary
end point (mean AR/C DSS over the entire GPS) or for
the key secondary end points, although trends in favor
of AIT were seen. The design of the current study was
Table 5 Adverse events experienced by 5% or more of all treated subjects
Treatment-emergent AEs Treatment-related AEs
AEs, no. (% of subjects experiencing) Placebo (n = 166) Grass AIT (n = 163) Placebo (n = 166) Grass AIT (n = 163)
Ear pruritus 1 (<1) 16 (10) 1 (<1) 16 (10)
Mouth edema 0 (0) 9 (6) 0 (0) 9 (6)
Oral pruritus 1 (<1) 29 (18) 1 (<1) 28 (17)
Nasopharyngitis 24 (14) 23 (14) 0 (0) 1 (<1)
Sinusitis 6 (4) 12 (7) 1 (<1) 0 (0)
URTI 15 (9) 17 (10) 0 (0) 0 (0)
Headache 12 (7) 8 (5) 1 (<1) 1 (<1)
Paraesthesia oral 2 (1) 14 (9) 2 (1) 14 (9)
Throat irritation 4 (2) 24 (15) 4 (2) 23 (14)
Urticaria 0 (0) 8 (5) 0 (0) 6 (4)
AE Adverse event, AIT Allergy immunotherapy tablet, URTI Upper respiratory tract infection.
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adults with grass pollen-induced AR/C that was
conducted in 8 European countries [8]. In that study,
grass AIT initiated an average of 26 weeks prior to the
start of the GPS significantly reduced AR/C symptoms
and medication use. The efficacy of grass AIT has been
demonstrated in 4 phase 2 and 3 trials conducted in
European subjects with AR/C due to grass pollen allergy
[8-11]; 2 large, placebo-controlled phase 3 studies in
North American subjects assessed symptoms during the
2009 GPS and found that pre- and co-seasonal treat-
ment with grass AIT was well tolerated and significantly
reduced AR/C symptoms and combined symptom and
medication score [12,13]. As in other trials of grass AIT
[8-13], there were no cases of anaphylactic shock in the
present study; epinephrine was administered to 3 sub-
jects, all of whom experienced symptoms within 10 mi-
nutes after the first dose of grass AIT and none of whom
showed signs of hypotension.
Post hoc analyses of the present trial were attempted, to
clarify what characteristics of its population or design
might have contributed to its failure to achieve the results
seen in successful trials of grass AIT. As in “real-world”
conditions, many subjects in the study were sensitized to
multiple allergens; approximately 50% of subjects were
sensitized to tree pollen, cat hair, and HDM. However,
subgroup analysis of subjects without these additional sen-
sitizations also failed to show significant differences be-
tween grass AIT and placebo. Further, the proportion of
subjects also sensitized to other common allergens in the
present trial was similar to those seen in other trials of
grass AIT, in which significant treatment effects were seen
[8-13]. A recent pooled analysis of data from 6 such
placebo-controlled randomized trials that found that re-
sponse to grass AIT treatment was similar between sub-
jects sensitized only to grass and subjects sensitized to
other common allergens [14]. Given these pieces of evi-
dence, it is considered unlikely that the efficacy of grassAIT was masked by the allergic responses to other com-
mon seasonal and perennial allergens.
However, several lines of evidence give support to the
idea that the symptoms reported by subjects in this trial
may not have been reflective of the influence of grass
pollen exposure. First, the pattern of symptoms during
the GPS was unexpected. In the current study, symptom
severity and medication use did not show any clear rela-
tionship to seasonal pollen exposure. By comparison,
symptoms generally mirrored pollen levels in other grass
AIT studies [8,9,12,13], ie, peak symptoms coincided
with peak pollen levels. Additionally, subjects in the
current trial showed high pre-seasonal symptoms,
whereas in other grass AIT trials symptoms were rela-
tively minimal in the pre-seasonal period [12,13]. A post
hoc analysis divided subjects into those with low pre-
seasonal symptoms (DSS ≤3; 33% of all subjects) and
those with high pre-seasonal symptoms (DSS >3; 67% of
all subjects). In those with pre-seasonal DSS ≤3, mean
DSS and mean DMS were both significantly lower over
the GPS in the grass AIT group compared with the pla-
cebo group (27%; p = 0.0327 and 68%; p = 0.0060, re-
spectively). The 27% reduction in symptom scores was
similar to the magnitude of the treatment effect seen in
other grass AIT trials (18% to 30% reduction in mean
DSS relative to placebo), [8,12] and as in these trials the
symptom scores closely corresponded to pollen expos-
ure. In subjects with pre-season DSS >3, no significant
differences between grass AIT and placebo were seen for
mean DSS or DMS (p >0.05). Along with the fact that
no relationship of symptoms to pollen count was ob-
served in the overall population, this suggests that the
symptoms reported in this trial were not primarily re-
flective of the effects of grass pollen exposure. It is con-
ceivable that subjects were suffering symptoms due to
some other unidentified cause, or that some subjects
understood poorly the standards by which they were to
score their symptoms.
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In this randomized, double-blind, placebo-controlled,
multicenter North American trial, grass AIT at a dose of
2800 BAU was not associated with significant improve-
ments in AR/C symptom or medication scores versus pla-
cebo over the GPS. These results contrast with the
efficacy repeatedly demonstrated in European and 2 other
North American trials of grass AIT for the treatment of
AR/C. Multiple possibilities have been explored as plaus-
ible explanations for the trial failure. Though no firm con-
clusions can be made, the high pre-seasonal symptoms,
lack of a relationship between pollen count and symptom
score in the presence of significant immunological re-
sponse, and the significant results of post hoc analysis ex-
cluding subjects with high pre-seasonal scores suggest
that the symptoms reported were not primarily reflective
of the effects of grass pollen exposure.Methods
Study design
This was a phase 3, double-blind, randomized, placebo-
controlled, parallel-group multicenter trial conducted at
28 sites in the United States (GT-14; clinicaltrials.gov
identifier NCT00421655). The study was conducted in
compliance with Good Clinical Practice guidelines. The
protocol was approved by institutional review boards for
each center. All subjects provided written informed con-
sent before any study activity began.
Treatment
Qualified subjects were randomized 1:1 to once-daily 2800
BAU of standardized Timothy grass AIT treatment (oral
lyophilisate, Phleum pratense, 75,000 standardized quality
tablet, containing approximately 15 μg of Phl p 5; ALK,
Hørsholm, Denmark) or placebo (identical in composition,
appearance, smell, and taste to active treatment but with
no grass pollen extract included) with no build-up dosing.
The tablets were supplied as fast-dissolving, neutral-
tasting oral lyophilisates for sublingual application. Excipi-
ents included gelatin, mannitol, and sodium hydroxide.
Treatment was administered sublingually, preferably in
the morning, for at least 8 to 16 weeks before the antici-
pated start of the GPS and continuing throughout the
GPS. Randomization was performed by in blocks by ALK,
using the SAS® system for Windows, which generates ran-
dom assignment of treatment groups to randomization
numbers. The randomization list was generated by a trial
statistician who was independent of the statistical analyses.
A 5-digit subject number was allocated to the subject at
the screening visit (visit 1). When a subject was random-
ized in the trial he/she was always to be assigned the low-
est available randomization number. The randomization
number was a 4-digit number.The first dose of study medication was administered at
the study site. Subjects were required to remain at the
study site for 20 to 30 minutes after administration of the
first dose to monitor for any AEs. Subsequent treatments
were self-administered by the subject once daily at home.
Eating and drinking were not allowed for 5 minutes after
administration. If any significant adverse event such as
wheezing, dyspnea, severe oral swelling, or sign of general-
ized anaphylactic reaction was observed or reported, the
investigator was to evaluate the subject to determine
whether treatment should be initiated; in such cases the
observation period was to be extended for at least an add-
itional 30 minutes, and upon leaving the clinic the subject
was instructed to contact the clinic immediately if the re-
action reoccurred or a new reaction appeared.
Study subjects
Subjects included in the study were 18 to 65 years of age
with a clinical history of grass pollen-induced AR/C, with
or without asthma, that interfered with daily activities or
sleep and was bothersome despite symptomatic treatment
during the GPS. At screening, subjects were required to
meet the following criteria: positive skin prick test re-
sponse to Phleum pratense defined as a wheal diameter
≥5 mm larger than that elicited by the saline control (stan-
dardized Timothy grass extract 100,000 BAU/mL, 5 mL
[ALK, Hørsholm, Denmark] administered to the inner
forearm with a DuoTip [Lincoln Diagnostics, Decatur, Ill];
positive control, histamine dihydrochloride 10 mg/mL
[ALK, Hørsholm, Denmark]); positive specific IgE against
P pratense (≥IgE Class 2 [≥0.7 kU/L; measured using the
DPC Immulite 2000, Siemens Medical Solutions Diagnos-
tics, Erlangen, Germany]); and an FEV1 of 70% or greater
of predicted value. Key exclusion criteria were as follows:
history of AR/C and/or asthma due to another allergen
potentially overlapping GPS; history of significant symp-
tomatic perennial or allergic rhinitis/asthma to an allergen
to which the subject was regularly exposed; immunother-
apy treatment within the previous 5 years; clinical history
of severe asthma, angioedema, or chronic/recurrent
rhinosinusitis or of chronic urticaria within the last year;
or history of anaphylaxis.
Although Bermuda grass sensitivity was not specifically
assessed (to exclude subjects with this allergy), only 3 of
28 study sites were located in the southern regions in
which Bermuda grass is known to pollinate.
Grass pollen season
One unique pollen count station recorded grass pollen
counts at each site. The start of the GPS for each site
was defined as the first 3 consecutive days with a pollen
count of 10 grains/m3/day or greater, and the end of the
GPS for each site was defined as the last day of the last
occurrence of 3 consecutive days with a pollen count of
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fined as the period of 15 consecutive recorded days with
the highest average among all possible 15 consecutive-day
averages across the GPS.
Assessments
The primary end point of the study was the average AR/C
symptom score during the entire GPS, calculated for each
subject as the sum of the individual AR/C DSS divided by
number of DSS diary recordings.
Key secondary end points were the average weekly
score on the RQLQ(S) over the entire GPS; the average
DMS, calculated as the sum of each day’s DMS divided
by the number of DMS diary recordings during entire
GPS; and the percentage of AR/C well days (days with-
out any AR/C rescue medication and a DSS of ≤2) dur-
ing the entire GPS.
The AR/C and asthma symptom scores were recorded
once daily in an electronic diary from the pre-seasonal visit
through the end of the GPS. The AR/C DSS was composed
of 6 symptoms (runny nose, blocked nose, sneezing, itchy
nose, gritty feeling/red/itchy eyes, and watery eyes) and the
asthma DSS was composed of 4 symptoms (cough, wheeze,
chest tightness/shortness of breath, and exercise-induced
symptoms). All symptoms were measured as follows: 0, no
symptoms; 1, mild symptoms; 2, moderate symptoms; or 3,
severe symptoms. Open-label AR/C rescue medication was
provided approximately 2 weeks before the start of the GPS
to be used in a stepwise sequence once the start of the GPS
had been confirmed and subjects reported a total AR/C
symptom score ≥6 (Table 6). Asthma medication (for sub-
jects with asthma) was provided as needed and use was
recorded; the asthma DMS was composed of the sum of
scores for short-acting β antagonist and inhaled corticoster-
oid use. Subjects were instructed to record their use of res-
cue medications in the electronic diary. The AR/C DMS
was composed of the sum of scores for oral antihistamine
and ocular antihistamine use. No other AR/C or asthma
medications were allowed (ie, parenteral, oral, nasal, andTable 6 Schedule for rescue medication
Step Rescue medication
Rhinoconjunctivitis
1 Desloratadine tablets, 5 mg, 1
2 Olopatadine eye drops, 1 mg




A Albuterol inhalation powder,
up to 2–4 inhalations twice d
B Fluticasone inhalation powde
1–2 inhalations up to twice d
Maximum daily asthma medication scoreinhaled corticosteroids, leukotriene antagonists, cromones,
decongestants, long-acting β2-agonists, or additional topical
or oral antihistamines). The RQLQ(S) was completed at
visit 4 and weekly during the GPS. A higher score indicates
more significant impairment.
Additional efficacy end points included AR/C DSS
over the peak GPS, nose and eye symptoms over the
peak and entire GPS, AR/C DMS over the peak GPS,
combined AR/C DSS and DMS over the peak and entire
GPS, AR/C DSS and DMS over the first 7 days of GPS,
AR/C symptoms by visual analogue scale (VAS) score
over peak and entire GPS, global evaluation of individual
AR/C symptoms and overall global evaluation, excellent
AR/C control (>50% well days), AR/C well days over
peak GPS, days without AR/C rescue medication use or
symptoms, asthma DSS over peak and entire GPS,
asthma DMS over peak and entire GPS, and asthma well
days (days without asthma rescue medication, with
asthma DSS ≤1) over peak and entire GPS.
Immunologic assessments
The serum was analyzed by ALK for determination of
antigen-specific antibodies and other immunologic pa-
rameters (IgE, IgG4, and IgE-blocking antibodies).
Immunologic tests were performed on blood collected
at the screening visit (visit 1), the pre-season visit (visit 4),
and at the end-of-season visit (visit 6). Blood samples were
analyzed by ALK by means of the ADVIA Centaur
Immunoassay system (Siemens Medical Solutions Diag-
nostics, Tarrytown, NY).
Safety
Safety was assessed through AEs that were spontan-
eously reported by subjects or observed by the investiga-
tor; at each site visit, investigators also asked the
subjects whether any problems had occurred since the
previous contact. AEs were graded by the investigators
as mild (transient symptoms, no interference with the
subject’s daily activities), moderate (marked symptoms,Score/dose unit Maximum daily score
tablet QD 6 (per tablet) 6




1 (per 1 inhalation) 8
r, 250 μg/dose,
aily
2 (per inhalation) 8
16
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or severe (considerable interference with the subject’s
daily activities, unacceptable). Safety assessments also
included hematology, blood chemistry and urinalysis
testing, physical examination, vital signs, and FEV1.
Statistical analysis
Sample size calculations were based on data from a previ-
ous grass AIT trial [8] in which the mean values and
standard deviations (SD) for the symptom score were 2.4
(1.6) for grass AIT and 3.4 (2.2) for placebo. Approxi-
mately 150 subjects per group, assuming a 20% dropout
rate, would detect a 24% reduction in mean DSS for grass
AIT compared with placebo at a 5% significance level and
with 90% power. The difference between the grass AIT
and placebo groups for DSS, DMS, and percentage of well
days was assessed by analysis of variance (ANOVA), with
treatment group as fixed effect and pollen region as ran-
dom effect. The confidence interval for the relative treat-
ment difference was estimated by bootstrapping using the
mean estimates. The weekly overall RQLQ(S) analysis was
performed using a repeated measurement ANOVA in-
cluding treatment group, week, and treatment-by-week
interaction as fixed effects, pollen area as a random effect,
and adjusting for subject variation. An AR(1) or com-
pound symmetry covariance structure was applied. All ef-
ficacy analyses were conducted on the intent-to-treat
population based on all randomized subjects who had data
available (at least 1 post-treatment diary data entry during
the entire GPS, or during peak GPS for end points
assessing peak GPS) for analysis. There was no imputation
of missing data, and subjects who withdrew prior to the
start of the GPS did not contribute to the efficacy analyses.
Safety analyses were conducted on all randomized sub-
jects. Differences in the immunological assessments be-
tween visits within treatment and differences between
treatments at each visit were estimated using a repeated
measurement model. The response variable in the model
was change from baseline. Treatment, visit, treatment by
visit interaction, and pollen area were included as fixed ef-
fects, and the adjustment for different error variation for
each group was performed. IgE and IgG4 values were
log10-transformed to obtain approximately normally dis-
tributed data. Differences between visits in immunological
measurements within each treatment were in addition
tested using a Student’s t-test; non-parametric tests of dif-
ferences between treatments were performed using a
Wilcoxon test. The principal statistical software used was
SAS®, version 8.2.
Abbreviations
AEs: Adverse events; AIT: Allergy immunotherapy tablet; ANOVA: Analysis of
variance; AR(1): Autoregressive covariance model (1); AR/C: Allergic rhinitis
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